Osteonecrosis of the Jaws in Patients Receiving Anti-Angiogenic Drugs and Chemotherapeutics: Literature Review and Case Reports

1. Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): Initial discovery and subsequent development. J Oral Maxillofac Surg. 2009, 67, 13-18.10.1016/j.joms.2008.10.00519371810Search in Google Scholar

2. Reid IR: Osteonecrosis of the jaw: Who gets it, and why? Bone, 2009, 44, 4-10.10.1016/j.bone.2008.09.01218948230Search in Google Scholar

3. Berenson JR, Hillner BE, Kyle RA, et al. American Society Of Clinical Oncology Clinical Practice Guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002, 20, 3719–36.10.1200/JCO.2002.06.037Search in Google Scholar

4. Delmas PD. The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatol. 2005,17,462-466.Search in Google Scholar

5. Aragon-Ching JB, Ning YM, Chen CC et al. Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration-resistant prostate cancer treated with antiangiogenic agents. Cancer Invest, 2009, 27, 221-226.10.1080/07357900802208608264813219235596Search in Google Scholar

6. Khosla S, Burr D, Cauley J et al. American Society for Bone and Mineral Research: Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res, 2007, 22, 1479-1491.10.1359/jbmr.0707onj17663640Search in Google Scholar

7. Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw – 2014 Update. J Oral Maxillofac Surg, 2014, 72(10), 1938-1956.10.1016/j.joms.2014.04.03125234529Search in Google Scholar

8. Estilo CL, Fornier M, Farooki A. et al. Osteonecrosis of the jaw related to bevacizumab. J. Clin. Oncol. 2008, 26, 4037-4038.10.1200/JCO.2007.15.5424Search in Google Scholar

9. Horie N, Kawano R, Kaneko T, Shimoyama T. Methotrexate-related lymphoproliferative disorder arising in the gingiva of a patient with rheumatoid arthritis. Austr Dent J, 2015, 60(3), 408-411.10.1111/adj.1223525302816Search in Google Scholar

10. Sung EC, Chan SM, Sakurai K, Chung E. Osteonecrosis of the maxilla as a complication to chemotherapy: a case report. Spec Care in Dentist, 2002, 22(4), 142-146.10.1111/j.1754-4505.2002.tb01178.x12449457Search in Google Scholar

11. Poxleitner P, Engelhardt M, Schmelzeisen R, Voss P. The prevention of medication-related osteonecrosis of the jaw. Deutsch Ärzteblatt Internat, 2017, 114(5), 63-69.10.3238/arztebl.2017.0063533147728241916Search in Google Scholar

12. Ebker T, Rech J, Von Wilmowsky C et al. Fulminant course of osteonecrosis of the jaw in a rheumatoid arthritis patient following oral bisphosphonate intake and biologic therapy. Rheumatology, 2013 52, 218-220.10.1093/rheumatology/kes35123238981Search in Google Scholar

13. Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates– histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Medi, 2006, 35(3), 155-160.10.1111/j.1600-0714.2006.00391.x16454811Search in Google Scholar

14. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4–25.10.1210/edrv.18.1.0287Search in Google Scholar

15. Maeda K, Chung YS, Ogawa Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer (Phila), 1996;77:858-63.10.1002/(SICI)1097-0142(19960301)77:5<858::AID-CNCR8>3.0.CO;2-ASearch in Google Scholar

16. Yamamoto S, Yasui W, Kitadai Y, et al. Expression of vascular endothelial growth factor in human gastric carcinomas. Pathol Int, 1998;48:499-506.10.1111/j.1440-1827.1998.tb03940.xSearch in Google Scholar

17. Brunello A, Borgato L, Basso U, et al. Targeted approaches to triple-negative breast cancer: Current practice and future directions. Curr Med Chem 20: 605-612, 2013.10.2174/092986713804999321Search in Google Scholar

18. De Falco S, Antiangiogenesis therapy: an update after the first decade, Korean J Int Med, 2014, 29(1), 1-11.10.3904/kjim.2014.29.1.1Search in Google Scholar

19. Al-Husein B, Abdalla M, Trepte M, et al. Antiangiogenic therapy for cancer: an update, Pharmacotherapy, 2012 32(12), 1095-1111.10.1002/phar.1147Search in Google Scholar

20. Hopp RN, Pucci J, Santos-Silva AR, Jorge J. ONM after administration of intravitreous bevacizumab. J Oral Maxillofac Surg 2012, 70, 632–635.10.1016/j.joms.2011.02.104Search in Google Scholar

21. Greuter S, Schmid F, Ruhstaller T, Thuerlimann B. Bevacizumab-associated osteonecrosis of the jaw. Ann Oncol 2008, 19,2091-2092.10.1093/annonc/mdn653Search in Google Scholar

22. Serra E, Paolantonio M, Spoto G, et al. Bevacizumab-related osteneocrosis of the jaw. Int J Immunopathol Pharmacol 2009, 22, 1121–1123.10.1177/039463200902200429Search in Google Scholar

23. Guarneri V, Miles D, Robert N, et al. Bevacizumab and osteo-necrosis of the jaw: Incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 2010, 122, 181-818.10.1007/s10549-010-0866-3Search in Google Scholar

24. Hopp RN, Pucci J, Santos-Silva AR, Jorge J. ONM after administration of intravitreous bevacizumab. J Oral Maxillofac Surg 2012, 70, 632-635.10.1016/j.joms.2011.02.104Search in Google Scholar

25. Sato M, Ono F, Yamamura A, Onochi SN. A case of osteonecrosis of the jaw during treatment by bevacizumab for sigmoid colon cancer. Shokakibyo Gakkai Zasshi 2013, 110(4), 655-659.Search in Google Scholar

26. Tzermpos F, Ismail A, Pavli M, Tosios KI. Osteonecrosis of the mandible in a patient with lung adenocarcinoma undergoing anti-angiogenic therapy with bevacizumab. Oral Surg, 2016, 9(1), 40-46.10.1111/ors.12153Search in Google Scholar

27. McArthur HL, Estilo C, Huryn J, et al. Osteonecrosis of the jaw (ONJ) among intravenous (IV) bisphosphonate- and/ or bevacizumab-treated patients (pts) at Memorial Sloan-Kettering Cancer Center (MSKCC). J Clin Oncol 2008; 26, 9588.10.1200/jco.2008.26.15_suppl.9588Search in Google Scholar

28. Van Poznak C. Osteonecrosis of the jaw and bevacizumab therapy. Breast Cancer Res Treat, 2010, 122, 189-191.10.1007/s10549-010-0933-9297567120464477Search in Google Scholar

29. Fangusaro J, Gururangan S, Jakacki RI, et al. Bevacizumab-associated osteonecrosis of the wrist and knee in three pediatric patients with recurrent CNS tumors. J Clin Oncol 2013, 31, e24-e27.10.1200/JCO.2012.43.6733353239623169504Search in Google Scholar

30. Tabouret T, Gregory T, Dhooge M, et al. Long term exposure to antiangiogenic therapy, bevacizumab, induces osteonecrosis. Invest new drugs, 2015, 33(5), 1144-1147.10.1007/s10637-015-0283-x26311072Search in Google Scholar

31. Antonuzzo L, Lunghi A, Giommoni E, et al. Regorafenib also can cause osteonecrosis of the jaw. JNCI, 2016,108(4).10.1093/jnci/djw00226857267Search in Google Scholar

32. Melloni C, Tuttolomondo A, Anfosso A, et al. Sunitinib related osteonecrosis of the jaw (SURONJ): a rare occurrence? Eur J Plast Surg, 2016, 39(2), 161-162.10.1007/s00238-015-1112-3Search in Google Scholar

33. Garuti F, Camelli V, Spinardi L, et al. Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma. Tumori Journal, 2016, 102 (2_suppl), S69-S70.10.5301/tj.500050427079903Search in Google Scholar

34. Koch FP, Walter C, Hansen T, et al. Osteonecrosis of the jaw related to sunitinib. Oral and maxillofacial surgery, 2011, 15(1), 63-66.10.1007/s10006-010-0224-y20401503Search in Google Scholar

35. Agrillo A, Nastro Siniscalchi E, Facchini A, et al. Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: two case reports. Eur Rev Med Pharmacol Sci, 2012 16(7), 952-957.Search in Google Scholar

36. Schwartz HC. Osteonecrosis of the jaws: a complication of cancer chemotherapy. Head & neck surgery, 1982, 4(3), 251-253.10.1002/hed.28900403136896046Search in Google Scholar

37. Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann oncol, 2012, 23(5):1341-1347.10.1093/annonc/mdr43521986094Search in Google Scholar

38. Owosho, AA, Liang, STY, Sax, AZ, et al. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2018, 125(5), 440-445.10.1016/j.oooo.2018.02.003751802729580668Search in Google Scholar